Despite numerous clinical trials and pre-clinical developments, the treatment of glioblastoma
(GB) remains a challenge. The current survival rate of GB averages one year, even with an …

Abstract Poly (ADP-ribose) polymerase-1 (PARP-1) is a key enzyme in the DNA repair
process, and the overexpression of PARP-1 in several tumours makes this enzyme a …

Purpose Imaging the PARP expression using 18F probes has been approved in clinical
trials. Nevertheless, hepatobiliary clearance of both 18F probes hindered their application in …

The central paradigm of novel therapeutic approaches in cancer therapy is identifying and
targeting molecular biomarkers. One such target is the nuclear DNA repair enzyme Poly …

Background Triple-negative breast cancer (TNBC) lacks biomarkers for targeted therapy.
Auger emitters display the best therapeutic effect, if delivered directly into the nucleus …

With the development of positron emission tomography (PET) technology, a variety of PET
imaging agents labeled with radionuclide 18 F have been developed and widely used in the …

The genetic code to life is balanced on a string of DNA that is under constant metabolic and
physical stress from environmental forces. Nearly all diseases have a genetic component …

Immune checkpoint blockades have revolutionized the treatment landscape for several
cancer indications, yet they have not gained traction in a range of other tumors such as triple …

Simple Summary In parallel to the successful clinical implementation of PARP1/2 inhibitors
as anti-cancer drugs, which interfere with the DNA repair machinery, these small molecule …